Varian's "smart" imaging tool:
This article was originally published in Clinica
Executive Summary
Varian Medical Systems has received FDA 510(k) clearance for its Smart Segmentation technology, a radiotherapy treatment planning tool. It is designed to enable clinicians to reduce the amount of time needed to plan treatments including intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), stereotactic radiosurgery (SRS), brachytherapy, and proton therapy. The Palo Alto, California firm claims that the new Smart Segmentation feature, which has been added to Varian's Eclipse treatment planning product, is the world's first fully automatic tool that uses intelligent software to identify organs and other structures within diagnostic images of the thorax and male pelvis. The Smart Segmentation tool can automatically identify all of the structures of interest in less than 45 seconds. Previously, structures requiring radiotherapy or protection from radiotherapy had to be identified manually.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.